SIS
BCRX icon

Sound Income Strategies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sound Income Strategies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-427
Closed -$4K – 666
2026
Q1 		$4K Buy
427
+327
+327% +$2.54K ﹤0.01% 1926
2025
Q4 		$666 Buy
+100
New +$723 ﹤0.01% 2345

Other funds holding BCRX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sound Income Strategies's BCRX Position: Q2 2026 in Review

Sound Income Strategies sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 427 shares — an estimated $4K sold.

Sound Income Strategies first reported a position in BCRX in Q4 2025 and held it in 2 quarters. The position peaked at $4K in Q1 2026. 76 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Sound Income Strategies reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 427 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $4K.
  • Sound Income Strategies first reported a position in BioCryst Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's BioCryst Pharmaceuticals position peaked at $4K in Q1 2026.
  • 76 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.